Eptifibatide de Syndrome Coronarii Acuti Acuti 188627-80-7
Product Detail
| Nomen | Eptifibatide |
| CAS numerus | 18862-80-7 |
| Formulae hypotheticae | C35H49N11O9S2 |
| M. pondus | 831.96 |
| EINECS Number | 641-366-7 |
| Density | 1.60±0.1 g/cm3(praedicta) |
| Repono conditionibus | In sicco signati, copia in freezer, sub -15°C |
Synonyma
Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;EPTIFIBATIDE;N6- (Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-La-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2 (DISULFIDEBRIDGE,MPA1-CYS6).
Platelet Glycoprotein Antagonist
Etifibatide (integrilinum) est nova polypeptida glycoprotein IIb/IIIa recepta contra adversarios, quae inhibet aggregationem et thrombosin platelet, inhibendo ultimum iter commune aggregationis platelet.Comparatus cum anticorpore monoclonali abciximab, eptifibatide validiorem, magis directionalem et specificam ligaturam habet cum GPIIb/IIIa propter existentiam unius substitutionis amino acidi conservativae — lysinae pro arginine.Ergo effectum habere debet bonum therapeuticum in tractatione interventali syndromi coronarii acuti.Platelet glycoprotein IIb/IIIa receptor pharmaca antagonista multum explicata est, et nunc sunt 3 genera praeparationum quae in internationali clinico, abciximab, eptifibatide et tirofiban adhiberi possunt.).Parva experientia in usu glycoprotein glycoprotein GPIIb/IIIa receptae antagonistae in Sinis usus est, et medicamenta in promptu etiam valde limitata sunt.Unum tantum medicamentum, tirofiban hydrochloridum in foro est.Ergo nova lamina glycoprotein IIb amplificata est./IIIa receptor antagonistae sunt imperativi.Eptifibatide domestica est imitatio producta producta per Chengdu Sino Biological Products Co., Ltd.
Classification
Classification of Antiplatelet aggregatio Medicamenta
Antiplatelet aggregatio medicamentorum in tria genera dure dividi potest: 1. Cyclooxygenase-1 (COX-1) inhibitores, ut aspirin.2. Inhibere aggregationem inductam adenosinam diphosphatam (ADP), ut clopidogrel, prasugrel, cangrelor, ticagrelor, etc. prostaglandin EP3 receptor inhibitores, nuper compositi chemici compositi et excerpta efficax e medicina tradito Sinensi.
